they do need good knees in this part of the US

First 34 Last

Share
Profile

Follow
jimmymoggill

600 Posts.

145

25/01/23

05:35

Post #: 65864916
Share

Originally posted by Mozzarc: ↑

Hi Crusader,

From what I understand they open a number of sites across the country and begin recruiting and screening. Some places naturally are able to recruit quicker than others. Typically major metro are easier, some of the smaller centres can take time. It varies based on a number of factors such as population density, profile, age of typical resident in and around these centres etc etc.

However, take a look at a more illustrative example dealing with OA prevalence by age across USA...evenly distributed?

You'd think so...but not so in actuality:

The red star above is California. One of the more populated states in the USA but look at OA prevalence there, way down the list! I can easily see how this could be a recruitment problem, if one were to put too many recruiting centres in this one such state ...it would be harder to drive numbers specially at the start when no one knows what Zilosul is and how it works. though recruiting will get easier as waves go through and ppl chat.

I suspect Box Hill, Victoria, Aus. is a major player as they have had a closer association in past trials and studies with PAR and perhaps other OA studies so they can easily recruit quicker and in more numbers. However there are limits. We want an even spread across all, not 90% from one centre and 1% scattered over the remaining 50 sites for instance.

I also suggest that there are more post codes in the USA where they may want to increase recruitment drive rates more so than others.

Cheers
Mozz

Reference Used:
https://www.cdc.gov/arthritis/data_statistics/state-data-current.htm

Expand

they do need good knees in this part of the US

PAR Price at posting: $1.41 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Good habits matters when it comes to finances

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

There are more pages in this discussion • 46 more messages in this thread...

First 34 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 23.0¢		Change 0.000(0.00%)		Mkt cap ! $80.45M

Open	High	Low	Value	Volume
23.5¢	24.0¢	23.0¢	$122.3K	521.4K

Buyers (Bids)

No.	Vol.	Price($)
9	330565	23.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.5¢	50000	1

View Market Depth

No.	Vol.	Price($)
8	325565	0.230
7	100610	0.225
14	252316	0.220
6	73458	0.215
6	140050	0.210

Price($)	Vol.	No.
0.235	50000	1
0.250	29100	2
0.260	20000	2
0.270	13000	2
0.275	10000	1

Last trade - 16.10pm 19/08/2024 (20 minute delay)

PAR (ASX) Chart

they do need good knees in this part of the US

Fourfold skarn increase points the way to viable garnet project, says Pure

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

they do need good knees in this part of the US

Top Stories

Fourfold skarn increase points the way to viable garnet project, says Pure

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News